# US 2026/0218177 A1 · Modified double-stranded rna agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218177 A1
- Document ID: US20260218177A1
- Status: Published application
- Kind: A1
- Application number: 19/115,987
- Filed: 2023-09-29
- Published: 2026-07-30
- Earliest claimed: 2022-09-30
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Muthiah MANOHARAN; Shigeo MATSUDA; Atsushi MIKAMI; Dhrubajyoti DATTA
- Web page: https://patentgrep.com/patent/US20260218177A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/33: of the base
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/351: Conjugate
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/30: chemically synthesised
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

One aspect of the present disclosure relates to a dsRNA agent comprising a sense strand and an antisense strand sufficiently complementary to at least one portion of a mRNA of the target gene, each strand having 14 to 40 nucleotides, wherein the antisense strand comprises at least one TNA (threose nucleic acid) at position 1, counting from the 5′ end. Other aspects of the invention relate to a method of modulating the expression of a target gene in a cell and a method of treating a subject having a CNS disorder comprising administering to a cell or a subject the dsRNA agent.

## Claims

### Claim 1

A double-stranded RNA (dsRNA) agent capable of modulating the expression of a target gene, comprising a sense strand and an antisense strand sufficiently complementary to at least one portion of a mRNA of the target gene, each strand having 14 to 40 nucleotides, wherein:
the sense strand comprises at least one 2′-OMe modification at position 1, counting from the 5′ end; and
the antisense strand comprises at least one TNA (threose nucleic acid) at position 1, counting from the 5′ end.

### Claim 2 (depends on 1)

The dsRNA agent of claim 1, wherein the sense strand further comprises at least one 2′-OMe modification at position 2, counting from the 5′ end.

### Claim 3 (depends on 1)

The dsRNA agent of claim 1, wherein the dsRNA agent contains one or more ligands conjugated to at least one strand, optionally via a linker or carrier.

### Claim 4

A double-stranded RNA (dsRNA) agent capable of modulating the expression of a target gene, comprising a sense strand and an antisense strand sufficiently complementary to at least one portion of a mRNA of the target gene, each strand having 14 to 40 nucleotides, wherein:
one of the sense or antisense strand comprises at least one 4′-modified TNA (threose nucleic acid) having the structure of
wherein:
each R is independently an optionally substituted alkyl,
B is an optionally modified nucleobase, and
* represents the bond to H or to the internucleotide linkage to the subsequent nucleotide.

### Claim 5 (depends on 4)

The dsRNA agent of claim 4, wherein the dsRNA agent contains one or more ligands conjugated to at least one strand, optionally via a linker or carrier, wherein at least one ligand is a lipophilic moiety.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The dsRNA agent of claim 5, wherein at least one ligand is an ASGPR ligand.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

The double-stranded RNA (dsRNA) agent of claim 1, wherein
one or more lipophilic moieties are conjugated to at least one strand, optionally via a linker or carrier.

### Claim at position 10

11-13. (canceled)

### Claim 14 (depends on 5)

The dsRNA agent of claim 5, wherein the lipophilic moiety:
(i) is lipid, cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine,
(ii) contains a saturated or unsaturated C4-C30 hydrocarbon chain, and an optional functional group selected from the group consisting of hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne: or
(iii) is selected from the group consisting of:
wherein:
m is an integer of 0-8:
n is an integer of 1-21:
R2′ is H, OH, F, OMe, O-methoxyalkyl, O-allyl, O—N-methylacetamido, O-dimethylaminoethoxyethyl, or O-aminopropyl;
B is a modified or unmodified nucleobase;
W is an alkyl; and
R and R′ are each independently H or alkyl.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The dsRNA agent of claim 14, wherein the lipophilic moiety contains a saturated or unsaturated C4-C18 hydrocarbon chain, and wherein one or more lipophilic moieties are conjugated to one or more of the following internal positions: positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counting from the 5′ end of each strand.

### Claim 17

(canceled)

### Claim 18 (depends on 5)

The dsRNA agent of claim 5, further comprising a targeting ligand that targets a receptor which mediates delivery to a CNS tissue or an ocular tissue,
wherein the targeting ligand is selected from the group consisting of Angiopep-2, lipoprotein receptor related protein (LRP) ligand, bEnd.3 cell binding ligand, transferrin receptor (TfR) ligand, manose receptor ligand, glucose transporter protein, and LDL receptor ligand, or
wherein the targeting ligand is selected from the group consisting of trans-retinol, RGD peptide, LDL receptor ligand, and carbohydrate based ligands.

### Claim at position 16

19-21. (canceled)

### Claim 22 (depends on 1)

The dsRNA agent of claim 1, wherein the TNA has the structure of:
wherein each R is independently an optionally substituted alkyl, B is an optionally modified nucleobase, and * represents the bond to the internucleotide linkage to the subsequent nucleotide.

### Claim at position 18

23-31. (canceled)

### Claim 32 (depends on 22)

The dsRNA agent of claim 22, wherein B is one of the following:

### Claim 33 (depends on 22)

The dsRNA agent of claim 22, wherein B is
wherein Rb is a lipophilic moiety, optionally containing a saturated or unsaturated C4-C30 hydrocarbon chain, a carbohydrate, a folate, or a glutamate urea (PUPA).

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The dsRNA agent of claim 33, wherein Rb is one of the following:
Rb has a formula of
wherein
s is 1-10, and
Ln is one of the following:

### Claim 36

(canceled)

### Claim 37 (depends on 22)

The dsRNA agent of claim 22, wherein at least one TNA has a structure of
wherein:
(i) R is methyl substituted with hydroxyl, alkoxy, or alkoxyalkoxy,
(ii) R is C1-C3 alkyl substituted with one or more halogen groups,
(iii) R is methyl substituted with an alkenyl or alkynyl,
(iv) R is methyl substituted with a triazoryl group, wherein the triazoryl group has a N atom optionally substituted with one or more of C(O), N(H), alkyl, alkenyl, alkynyl, aryl, heteroaryl, a lipophilic moiety, a carbohydrate, and/or a vitamin, or
(v) R is methyl substituted with an amino group, optionally substituted with one or more of C(O), N(H), halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, a lipophilic moiety, a carbohydrate, and/or a vitamin,
and wherein R is in (R) or (S) configuration.

### Claim 38 (depends on 37)

The dsRNA agent of claim 37, wherein the TNA is a 4′-modified TNA having the structure of
wherein:
R1 is one of the following:
and
n is 1-10, or
wherein R1 is one of the following:

### Claim at position 26

39-47. (canceled)

### Claim 48 (depends on 22)

The dsRNA agent of claim 22, wherein at least one TNA is a 4′-modified TNA having a structure of
wherein R is methyl, and wherein:
(i) R is in (S) configuration, wherein at least one 4′-modified TNA is at one of positions 1-9 and 12-15 of the sense strand, counting from the 5′ end of the sense strand;
(ii) R is in (S) configuration, wherein at least one 4′-modified TNA is at one of positions 3, 5-11, 14, 16, 18, and 20 of the antisense strand, counting from the 5′ end of the antisense strand;
(iii) R is in (R) configuration, wherein at least one 4′-modified TNA is at one of positions 1-10 and 12-21 of the sense strand, counting from the 5′ end of the sense strand; or
(iv) R is in (R) configuration, wherein at least one 4′-modified TNA is at one of positions 2-10, 19-21, and 23 of the antisense strand, counting from the 5′ end of the antisense strand.

### Claim at position 28

49-52. (canceled)

### Claim 53 (depends on 1)

The dsRNA agent of claim 1, wherein the internucleotide linkage between the nucleotides at position 1 and position 2 of the 5′ end of the antisense strand is not a phosphorothioate linkage.

### Claim 54 (depends on 1)

The dsRNA agent of claim 1, wherein the 5′ end of the antisense strand does not contain a phosphate or phosphate mimic.

### Claim 55 (depends on 1)

The dsRNA agent of claim 1, wherein the sense and antisense strands are each 19 to 25 nucleotides in length; wherein the dsRNA agent comprises a single-stranded overhang of 1, 2 or 3 nucleotides in length on one of the termini, and a blunt end on the other termini.

### Claim 56 (depends on 55)

The dsRNA agent of claim 55, wherein the sense strand is 21 nucleotides in length, and the antisense strand is 23 nucleotides in length, wherein the strands form a double-stranded region of 21 consecutive base pairs having a 2-nucleotide long single-stranded overhangs at the 3′-end.

### Claim at position 33

57-58. (canceled)

### Claim 59 (depends on 1)

The dsRNA agent of claim 1, wherein:
the sense strand comprises at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5′ end of the sense strand;
the antisense strand comprises at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 3′ end of the antisense strand; and/or
the antisense strand comprises at least two phosphorothioate internucleotide linkages between the first five nucleotides counting from the 5′ end of the antisense strand.

### Claim at position 35

60-61. (canceled)

### Claim 62 (depends on 1)

The dsRNA agent of claim 1, wherein at least one strand comprises one or more phosphorodithioates (PS2) linkages.

### Claim at position 37

63-64. (canceled)

### Claim 65 (depends on 1)

A method of modulating the expression of a target gene in a cell, comprising administering to said cell, the dsRNA agent of claim 1, wherein the cell is within a subject, and wherein the cell is a hepatic cell or an extrahepatic cell.

### Claim at position 39

66-68. (canceled)

### Claim 69 (depends on 65)

The method of claim 65, wherein the dsRNA agent is administered intrathecally or intravitreally, and wherein the method reduces the expression of a target gene in a brain or spine tissue, or in an ocular tissue.

### Claim at position 41

70-74. (canceled)

### Claim 75

A method of treating a subject having a CNS disorder, comprising:
administering to the subject, optionally extrahepatically, a therapeutically effective amount of a double stranded RNA (dsRNA) agent capable of modulating the expression of a target gene, thereby treating the subject,
wherein the dsRNA agent comprises a sense strand and an antisense strand sufficiently complementary to at least one portion of a mRNA of the target gene, each strand having 14 to 40 nucleotides, and wherein the antisense strand comprises at least one TNA (threose nucleic acid) at position 1, counting from the 5′ end; and
wherein the CNS disorder is selected from the group consisting of alzheimer, amyotrophic lateral schlerosis (ALS), frontotemporal dementia, huntington, Parkinson, spinocerebellar, prion, and lafora.

### Claim at position 43

76-78. (canceled)
